Alopecia Areata Clinical Trials 2022

Browse 48 Alopecia Areata Medical Studies Across 165 Cities

4 Phase 3 Trial · 359 Alopecia Areata Clinics

Reviewed by Michael Gill, B. Sc.
Photo of maryland 1
Phase-Based Progress Estimates
1
Effectiveness
2
Safety

Ruxolitinibfor Alopecia Areata

Bethesda, MD
Any Age
All Sexes
Background: Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) is a problem of the immune system. In people with APECED, the immune system makes a mistake and attacks the body. Some people with APECED have a type of hair loss called alopecia areata (AA). No drugs are approved to treat AA. Objective: To see if a study drug (ruxolitinib) can help hair regrowth in people with APECED-associated AA and if it can improve other symptoms caused by the immune system s attack to the body. Eligibility: People aged 12 to 65 years with APECED and severe AA. Design: Participants will be in this study for up to 10 months. They will have 5 in-person visits and 6 televisits, each about 4 weeks apart. One in-person visit may be up to a 10-day stay in the hospital. The first in-person visit will include screening. Participants will have a physical exam. They will have blood tests. Photographs may be taken of their skin. They will answer questions about their quality of life. Participants will begin taking the study drug during their hospital stay. They will take the pills by mouth twice a day for 8 months. Researchers may take tissue samples from participants scalp, gums, and lower lip. Participants may provide samples of urine, stool, nail clippings, and saliva. They may have an eye exam and an ultrasound exam of their abdomen. Some tests may be repeated in subsequent in-person visits. In telehealth visits, participants will answer questions about how they are feeling. They will describe and send photos of hair regrowth. They will be asked to have blood drawn and the results sent to the researchers.
Phase 2
Recruiting
25 Alopecia Areata Clinical Trials Near Me
New York, NY
Rochester, NY
Houston, TX
Bethesda, MD
More Trial Locations
An interactive map to display trial locations for Icahn School of Medicine at Mount Sinai, UR Dermatology at College Town, The University of Texas Health Science Center at Houston, National Institutes of Health Clinical Center, and 243 more locations.
Most Popular References for Alopecia Areata Clinical Trials
Frequency
Citation
Top Hospitals for Alopecia Areata Clinical Trials
Location
Active Alopecia Areata Clinical Trials
All Time Trials for Alopecia Areata
First Recorded Alopecia Areata Trial
Trials
Icahn School of Medicine at Mount Sinai, New York, New York
5
14
2015
California Dermatology & Clinical Research Institute, Encinitas, California
4
6
2018
University of California, Irvine, Irvine, California
4
5
2017
Top Treatments for Alopecia Areata Clinical Trials
Treatment Name
Active Alopecia Areata Clinical Trials
All Time Trials for Alopecia Areata
First Recorded Alopecia Areata Trial
Trials
Top Cities for Alopecia Areata Clinical Trials
City
Active Alopecia Areata Clinical Trials
Top Active Site for Alopecia Areata Clinical Trials
Trial List
New York, New York
10
Icahn School of Medicine at Mount Sinai
Houston, Texas
9
Suzanne Bruce and Associates, PA
San Antonio, Texas
9
Progressive Clinical Research
Portland, Oregon
9
NW Dermatology Institute
Minneapolis, Minnesota
8
University of Minnesota Department of Dermatology
Most Recent Alopecia Areata Clinical Trials
Phase 3 Alopecia Areata Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
4/4/2019
Phase 2 & 3
Pediatric Alopecia Areata Clinical Trials
Senior Friendly Alopecia Areata Clinical Trials
Recently Completed Studies with FDA Approved Treatments for Alopecia Areata
Treatment
Year
Mechanism of Action
Sponsor
Active Alopecia Areata Clinical Trials
CTP-543, 12 mg BID
2021
Concert Pharmaceuticals
0
TDM-105795
2021
Technoderma Medicines Inc.
0
CTP-543, 12 mg BID
2020
Concert Pharmaceuticals
0

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 18th, 2021

Last Reviewed: August 25th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.